Quick Facts

• Supports temporary relief of minor pain conditions on the skin.
• Used to manage discomfort from minor burns, scrapes, and insect bites.
• May be utilized to facilitate topical anesthesia of mucous membranes for certain procedures.

---

What Xylocaina Spray treats: main uses and benefits

Xylocaina Spray (lidocaine) is applied to the skin and mucous membranes to offer localized relief from discomfort. Its primary use involves the temporary mitigation of pain associated with minor skin irritations, such as small cuts, minor burns, and insect bites.

In therapeutic settings, the spray formulation is utilized for the production of topical anesthesia of mucous membranes, particularly within the respiratory or genito-urinary tracts, prior to certain medical or diagnostic procedures. This application assists in managing sensitivity and may support patient comfort during these evaluations. The medication's purpose is to temporarily reduce sensation in the treated area, which contributes to the relief of local pain. The proper application of this product is restricted to the indicated uses and should align with professional healthcare guidance.

Who can and cannot use Xylocaina Spray — Official Regulatory Information

The eligibility to use Xylocaina Spray (Lidocaine) is strictly defined by regulatory guidelines concerning patient status and pre-existing conditions.

---

Populations Excluded (Contraindicated)

The medicine is contraindicated for any individual with a known hypersensitivity or allergy to lidocaine, other amide-type local anesthetics, or any of the product's excipients.

---

Age and Special Population Restrictions

Use is generally established for adults and adolescents (age geq 12 years). The spray is not recommended for children under 3 years of age as stated in official labeling. Caution and a reduction in dose are mandated for elderly and acutely ill/debilitated patients due to increased sensitivity and altered physiological status.

---

Conditional Use and Cautionary Status

Eligibility is restricted and requires caution in patients with severe hepatic impairment (liver disease) or severe renal dysfunction, as well as those with impaired cardiovascular function (like heart block or severe shock). Extreme caution is required if the area of application is covered by septic or severely traumatized mucosa.

---

Pregnancy and Lactation Eligibility

Official labeling regards use during pregnancy as conditional; it should be used only if clearly needed and safer alternatives are unavailable. During lactation, use is generally considered acceptable at therapeutic dose levels, although the substance is known to be excreted in breast milk.

Interactions with other medicines and products

This section outlines the official interaction patterns for Xylocaina Spray (Lidocaine) as documented in government regulatory sources.

Interaction Scope

Property	Official Regulatory Information
Medicinal product categories with documented interactions	CYP1A2 Inhibitors, CYP3A4 Inhibitors, other Local Anesthetics, Antiarrhythmic Agents (amide-type), Class III Antiarrhythmic Drugs, certain Beta-adrenoceptor Blocking Agents, Cimetidine, and Muscle Relaxants.
Specific interacting medicines (if explicitly listed)	Fluvoxamine, Ciprofloxacin, Erythromycin, Itraconazole, Mexiletine, Propranolol, Amiodarone, and Suxamethonium.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic interaction via reduced clearance (CYP inhibition) leading to increased plasma concentration. Pharmacodynamic interaction causing additive systemic effects.
Timing-based interaction rules (if applicable)	None explicitly documented as mandatory time separation in regulatory labels.
Population-specific interaction notes (if applicable)	Interactions with drugs that reduce clearance are generally considered of no clinical importance following short-term treatment at recommended spray doses.

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification	Contraindicated Combinations: None listed solely due to interaction risk. Use-with-Caution Combinations: Co-administration with CYP inhibitors or other amide-type anesthetics/antiarrhythmics.
Regulatory basis	FDA Prescribing Information, EMA Summary of Product Characteristics (SmPC), and national regulatory agency labels.

Official Interaction Statements:

• Co-administration with CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) can increase the plasma concentration of Lidocaine due to reduced metabolic clearance.
• The use of Xylocaina Spray alongside other local anesthetics or agents structurally related to Lidocaine (e.g., mexiletine) poses a risk of additive systemic effects.
• Close surveillance, such as ECG monitoring, is required for co-administration with Class III Antiarrhythmic Drugs (e.g., amiodarone).

Connection to the overall interaction profile: Regulatory documents define the interaction structure primarily through a pharmacokinetic pattern involving reduced metabolic clearance by hepatic enzymes and a pharmacodynamic pattern causing additive systemic effects with related drugs. These constraints focus on identifying interacting medicinal products and specifying the required monitoring for certain high-risk combinations.

Blocking the Nerve Signal at the Molecular Level

Xylocaina Spray exerts its primary effect by acting as an inhibitor of voltage-gated sodium channels ( Na v) found on the membranes of peripheral nerve cells. The active ingredient, lidocaine, enters the nerve fiber and binds inside the channel pore, locking the channel into an inactive state. This molecular action is the initial step in the mechanistic cascade.

---

Inhibiting the Action Potential Cascade

The channel blockade prevents the necessary influx of sodium ions required for the nerve cell to depolarize and generate an action potential (electrical impulse). This stops the electrical signal from propagating along the nerve axon toward the central nervous system. This highly localized cascade involves interfering with neural electrical signaling.

---

Resulting Physiological Effect: Reversible Loss of Sensation

The consequence of interrupting the action potential cascade is the localized, reversible cessation of sensory input. This mechanism results in the interruption of pain signaling (nociception) and other sensory signals, leading to a state of functional nerve block in the treated area.

Xylocaina Spray (Lidocaine base) is designated for topical application to accessible mucous membranes, such as those within the oral cavity, pharynx, larynx, or genito-urinary tract, to achieve surface anesthesia. The product is a metered-dose pump spray that delivers 10 mg of Lidocaine base with each actuation, and its use is reserved as a single course of application immediately preceding a medical or diagnostic procedure. The short duration of action—typically 10 to 15 minutes after a 1 to 3 minute onset—governs the timing of administration.

The administration protocol follows specific limits. For a single adult procedure, the maximum total dose should not exceed 20 spray applications (200 mg), though minor procedures like those in dental practice often require only 1 to 5 applications.

Specific instructions govern the technique of use. The pump dispenser must be primed with 1 to 3 initial actuations before the first use of the bottle. Furthermore, it is deemed unnecessary to dry the site prior to application. The product must always be applied using the supplied nozzle, which is for single patient, single use only, and is not to be used on the cuffs of plastic endotracheal tubes.

Standard regimens are modified for certain patient groups. Reduced doses are required for elderly, debilitated, or acutely ill patients to align with their physical condition. For pediatric patients, the maximum recommended dose is restricted to 3 mg/kg of body weight per day, and the product is generally not recommended for children under 3 years of age.

Xylocaina Spray: Recent Clinical Evidence

Xylocaina Spray, which contains the active substance lidocaine, is a local anesthetic used to provide surface numbing (anesthesia) to accessible mucous membranes before medical or dental procedures. Its action involves stabilizing the neuronal membrane to temporarily block the initiation and conduction of nerve impulses, thus achieving its numbing effect.

---

Primary Indications and Usage

Clinical evidence supports the use of the spray for surface anesthesia in several medical contexts. These applications include:

• Otolaryngology: Anesthesia prior to minor, non-invasive procedures in the nasal cavity, pharynx, and larynx, such as laryngoscopy and rhinoscopy.
• Gastrointestinal and Respiratory Procedures: Numbing the oropharyngeal and tracheal areas to reduce reflex activity (like gagging or coughing) and facilitate the insertion of instruments during procedures like endoscopy, bronchoscopy, and endotracheal intubation.
• Dental Practice: Use on mucous membranes to achieve local anesthesia before minor dental procedures or injections.
• Obstetrics: Utilized as a supplemental agent for pain control during certain procedures.

---

Pharmacokinetic Profile (Onset and Duration)

Studies evaluating the properties of topical lidocaine spray show a rapid profile suited for short procedures. The onset of the numbing effect typically occurs within 3 to 5 minutes of application to the mucous membrane. The duration of this effect is variable depending on the site of application and concentration, but generally lasts between 10 to 30 minutes.

---

Ongoing Research

Clinical trials continue to investigate the role of topical lidocaine spray in reducing pain associated with common procedures, such as:

• Gynecological Procedures: Trials have examined the use of the spray to manage pain experienced during endometrial biopsy or intrauterine device (IUD) insertion.
• Intravenous Access: Research is assessing the effectiveness of lidocaine spray in minimizing local pain caused by the insertion of an intravenous (IV) catheter.

Key Studies & References

1. Lidocaine Spray versus Other Forms for Local Anesthesia in Upper Gastrointestinal Endoscopy: A Systematic Review and Meta-analysis
2. Lidocaine - StatPearls [Internet] (Pharmacokinetics, Onset, Duration, and Indications)
3. Lidocaine spray on an endoscope immediately before insertion improves patient tolerance to endoscopy: A single center, clinical observational study

Common questions about Xylocaina Spray (FAQ)

Q: Is Xylocaina Spray used for general pain relief, or only for procedures?

Regulatory documents indicate that Xylocaina Spray is designated for surface anesthesia of accessible mucous membranes only in connection with medical or diagnostic procedures. Official product information does not include general or chronic pain relief as an indicated use for this spray.

Q: What is the difference between Xylocaina Spray and other lidocaine topical forms like gels or ointments?

The spray is a metered-dose mucosal spray designed to deliver a specific, controlled amount of the active substance (10 mg) with each actuation. This dosage form is specialized for application over a targeted surface area, unlike gels or ointments, which are different forms of topical application.

Q: What are the rare but serious signs of a systemic reaction to Xylocaina Spray?

While rare, serious systemic effects are documented and linked to high plasma concentrations of the active ingredient. Documented serious effects include signs related to the nervous system (such as convulsions or confusion) and the cardiovascular system (such as low blood pressure or slow heart rate). Anaphylactic shock is also documented.

Q: What does a patient need to know about possible interactions with beta-blockers and Xylocaina Spray?

Co-administration with certain medications, such as Beta-adrenoceptor Blocking Agents (a type of heart medicine), is documented in official sources. These medicines can potentially increase the plasma concentration of the spray's active ingredient in the body due to a reduction in its metabolic clearance.

Q: Can the spray be used if a person has a history of liver or kidney problems?

Official regulatory documents advise caution and the use of reduced doses for patients with severely impaired hepatic (liver) or renal (kidney) function. These conditions can increase a person’s susceptibility to potential systemic effects.

Q: Is there evidence available about using Xylocaina Spray during pregnancy?

Official labeling advises that use during pregnancy is conditional; it should be used only if the benefit is determined to outweigh the potential risks and if clearly needed.

Q: Does the active ingredient in Xylocaina Spray pass into breast milk?

Studies and official information indicate that the active substance is known to be excreted in breast milk. However, use during lactation is generally considered acceptable when the product is used at recommended therapeutic dose levels.

Q: Does Xylocaina Spray have any influence on a person's ability to drive or operate machinery?

The drug is documented to cause potential adverse reactions such as dizziness or confusion, which are nervous system effects. These effects are documented to potentially influence the ability to drive or operate machinery.

Q: Is it expected to feel dizzy or drowsy after using Xylocaina Spray?

Dizziness is documented as a potential systemic side effect in official regulatory documents. Other Nervous System disorders are also listed as possible adverse reactions.

Q: Are there special considerations for using Xylocaina Spray in elderly patients?

Yes, regulatory documents mandate that reduced doses are required for elderly or acutely ill/debilitated patients. This adjustment is necessary to align with their physical condition and potential for reduced physiological clearance of the medication.

Q: Does Xylocaina Spray contain alcohol or other inactive ingredients that might cause a reaction?

The solution contains several inactive ingredients, or excipients, in addition to the active substance (lidocaine). Official product details indicate that the solution contains ethanol (alcohol), polyethylene glycol 400, and water.

Q: Can Xylocaina Spray be applied to broken skin or open cuts?

Regulatory documents indicate the spray is primarily for use on accessible mucous membranes. Caution is advised if the application site is covered by septic or severely traumatized mucosa due to an increased risk of systemic absorption of the drug into the body.

Q: Is the product typically administered by a healthcare professional or self-applied by the patient?

The product is indicated for use to provide surface anesthesia prior to medical or diagnostic procedures, such as endoscopy or dental work. The setting for these procedures suggests administration by a healthcare professional.

Q: How should Xylocaina Spray be stored according to official recommendations?

Official recommendations include storing the product at controlled room temperature (typically 20 C to 25 C) in the original container, avoiding excess heat and moisture. It must also be kept secured and out of the reach of children.

Q: Can Xylocaina Spray still be used if it is past its expiry date?

Regulatory guidance for all pharmaceuticals mandates that products must not be used after the expiration date printed on the packaging. Use of expired medication is strongly discouraged by official sources.

Q: Does Xylocaina Spray have a specific flavor or scent, such as menthol or banana?

Official product descriptions indicate that the spray solution may have a menthol and banana flavour.

Q: Can Xylocaina Spray be used on the skin for things like insect bites or sunburn?

Regulatory documents indicate the product is specifically designated for surface anesthesia of accessible mucous membranes, such as the mouth, throat, or nasal passages. It is not indicated for general application to the skin, such as for application to insect bites or sunburn.

Storage and Disposal of Xylocaina Spray

Xylocaina Spray must be stored under controlled room temperature, typically defined as 20°C to 25°C (68°F to 77°F). It is essential to keep the product in its original container and secure it in a cool, dry place, avoiding excess heat and moisture, with a prohibition on storage above 25°C. For safety, the spray must be kept out of the reach and sight of children.

Handling and Disposal

Proper handling includes ensuring the supplied spray nozzles, which are single-patient and single-use, are not reused. Unused or expired Xylocaina Spray must not be disposed of in household trash or down the drain. Disposal must follow local, state, and federal requirements for pharmaceutical or hazardous waste, often necessitating return to a pharmacist or designated collection facility.